|
市場調查報告書
HIV市場預測
HIV Market Forecast
|
本報告已在2012年03月16日停止出版。
更改為出版
HIV Market Forecast
出版日期 : 2012年02月
商品編碼: 234116
全球七大醫藥用品市場抗逆轉錄病毒藥物的販售，從2005年到2009年平均以10.8%的年率成長，並在2009年達到118億美金的記錄。
本報告針對全球HIV治療藥物七個主要市場相關預測（2010∼2019年），提供HIV治療藥物市場動向變化、主要品牌成功因素、後期實驗產品商業化可能性，目錄介紹如下。
概要
預測方法
免責事項
Abstract
Introduction
n 2009, HIV antiretroviral sales across the seven major markets totalled $11.8 billion, growing at a CAGR of 10.8% between 2005 and 2009. While new cross-class fixed dose combinations will ensure market growth until 2015, Datamonitor expects major patent expiries and rising pressure to reduce healthcare costs to trigger a decline in HIV sales in the second half of the forecast period until 2019.
Reasons to Purchase
- Understand the changing market dynamics of HIV drugs, success factors for leading brands and the commercial potential of late stage pipeline products.
- Assess the impact of events such as patent expiries and new product launches on individual brands and the overall HIV antiretroviral market.
- Obtain full country, class and product-specific forecasts of currently marketed and pipeline antiretrovirals from 2010 to 2019.
Table of Contents
OVERVIEW
This product contains forecasts for antiretroviral drugs for Human Immunodeficiency Virus (HIV) across the seven major markets from 2010 to 2019. It has been designed for delivery in an excel data pack format.
- The associated report can be found under Latest Research in the Knowledge Center, through the search function or by contacting your sales representative.
- Introduction
- The number of antiretroviral drugs reaching sales over $400m across the seven major markets (US, Japan, France, Germany, Italy, Spain, UK) will decline from ten in 2009 to six in 2019. The dominance of cross-class fixed dose combinations (FDCs) will make it increasingly difficult for stand-alone agents to penetrate the crowded HIV market. Datamonitor expects the FDC Truvada/rilpivirine to become the best-selling antiretroviral in HIV, reaching sales of $3.5 billion in 2019. Shionogi's/GlaxoSmithKline's integrase inhibitor S/GSK1349572 will become the most successful stand-alone pipeline agent.
- Scope of this research
- Research and analysis highlights
- Key reasons to read this report
Forecasting Methodology
- The forecasting model:
- General event information:
- Event selection and quantification:
- Event parameters:
Disclaimer
|
